SPEAKERS

SPEAKERS

Nicole Crisp, NP

Nurse Practitioner
Cross Cancer Institute
Edmonton, AB

Nicole Crisp is a Nurse Practitioner working at the Cross Cancer Institute in Edmonton, Canada, with experience in acute leukemia, myelodysplasia and stem cell transplantation. She spent several years working internationally in New Zealand and the UK, with dedicated training from the Royal Marsden School of Cancer Nursing. She is an advocate and member of the International Nurse Leadership Board for the Myelodysplastic Syndromes Foundation. Nicole has several published articles on a selection of interests,  including the development of home chemotherapy and home transfusion programs, quality of life in patients with hematologic malignancies, and the evidence for (and against) medical cannabinoids in oncology. In order to get the energy to maintain everything previously described, she enjoys spending time with her three children and competing in triathlons.

Dr. Matthew S. Davids, MD, MMSc.

Associate Professor of Medicine
Harvard Medical School
Director, Clinical Research, Division of Lymphoma
Dana Farber Cancer Institute
Boston, MA

After obtaining an A.B. cum laude in chemistry at Harvard College, Dr. Davids completed his M.D. cum laude at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Masters in Medical Science (M.M.S.c.) at Harvard Medical School. He is an attending physician in the Division of Lymphoma, where he serves as the Director of Clinical Research, as well as Associate Director of the CLL Center. He is also an Associate Professor of Medicine at Harvard Medical School, and attends on the inpatient hematologic malignancies service at Brigham and Women’s Hospital. Dr. Davids has an active translational research program in CLL and non-Hodgkin lymphoma, focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B cell receptor pathway kinases, and other novel agents, as well as utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.

Professor Andrew Davies, BSc (Hons), BM (Hons), FRCP, PhD

Professor of Haematological Oncology
Consultant in Medical Oncology
Cancer Sciences Unit, Faculty of Medicine
University Hospital Southampton
Southampton, UK

Andrew Davies is a Professor in Haematological Oncology and Consultant Medical Oncologist in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton, United Kingdom.  He was awarded honours in medicine, and also gained a first-class Bachelor of Science degree in Molecular Biology from the University of Southampton. He went on to train in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.

Professor Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena.  He has extensive experience in early phase trials, including leading several first in man lymphoma studies. He is the former Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Research Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults.

Tristin Hamilton, BScN, MN, NP

Cross Cancer Institute
Research Coordinator – University of Alberta
Edmonton, AB

Tristin Hamilton has been working in oncology since March 2020, following completion of her MN in 2019 at Athabasca University. She has a BA in Political Science from the University of Alberta, and is an Army veteran of the Canadian Armed Forces (CAF), having served as a Medic until 2012. She also a research coordinator with Heroes in Mind, Advocacy and Research Consortium (HiMARC) at the University of Alberta, focused on treating moral injury and PTSD in military and essential service provider populations.

Since joining Alberta Cancer Care, Tristin has helped implement the first Community Cancer Clinic where care is provided entirely via telehealth in Lloydminster, AB. Tristin was a panel member of the CANO 2021 symposia and NACIC 2021 conference, discussing optimization of virtual care delivery for patients and caregivers. She has a great passion for empowering patients and staff through enhanced education, communication, and teamwork.

Dr. Steven Horwitz, MD

Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Centre
New York, NY

Dr. Steven Horwitz is an Associate Attending in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City. He earned his medical degree at Case Western Reserve University School of Medicine, completed an internship and residency in internal medicine at the University of Rochester/Strong Memorial Hospital, and then completed a fellowship in medical oncology at Stanford University Medical Center.

Much of his current research is dedicated to investigating targeted or immunotherapeutic approaches to try to identify better, and often less toxic treatments for individuals with T-cell lymphomas. His research also focuses on better understanding mechanisms of response and resistance to novel drugs in T-cell lymphoma to help provide individualized treatments in the future.

Dr. Horwitz participates in several national, and international committees and consortiums dedicated to the understanding and advancement of treatment for T-cell lymphoma. Since 2017 he has been the Chair of the NCCN panel on Guidelines for Treatment of T-Cell/Primary Cutaneous B-Cell Lymphomas.

Dr. Manali Kamdar, MD

Associate Professor of Medicine
University of Colorado School of Medicine
Aurora, CO

Dr. Kamdar obtained her medical degree from Mumbai, India, and subsequently completed a residency in Internal Medicine and a fellowship in Hematology and Oncology at the East Carolina University in Greenville, North Carolina. She then completed another fellowship in lymphoid malignancies and bone marrow transplantation at Stanford University.
Currently, Dr. Kamdar is an Associate Professor of Medicine at the University of Colorado School of Medicine and serve as the Clinical Director of the lymphoma program. Her clinical and research interests include B-cell lymphomas, particularly refractory diffuse large B-cell lymphoma, mantle cell
lymphomas, and other indolent lymphomas. In addition to seeing patients with
lymphoma in clinic, Dr. Kamdar’s research involves conducting clinical trials of novel drugs, including immunotherapy and combinations in these diseases.

Dr. Thomas Kipps, MD, PhD

Professor of Clinical Medicine
Deputy Director of Research
Evelyn & Edwin Tasch Chair in Cancer Research
University of California
San Diego, California

Dr. Thomas Kipps is Distinguished Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, Director of the Center for Novel Therapeutics, and Deputy Director of Research Operations at the UC San Diego’s Moores Cancer Center.  Dr. Kipps is a two-time awardee of a Specialized Center of Research (SCOR) in Leukemia grant from the Leukemia and Lymphoma Society, a two-time awardee of the NIH MERIT Award, and principal investigator of the CLL Research Consortium (CRC), which directed inter-institutional research among the leading investigators in CLL from across the country and abroad. Dr. Kipps is a core member of the international workshop on CLL (iwCLL) and an awardee of the Rai/Binet medal for outstanding contributions to the field of leukemia research.  Dr. Kipps is the current Chair of the NCI Developmental Therapeutics Study Section and Associate Editor for Leukemia. He has received continuous peer-reviewed, extra-mural funding for research throughout his career and maintained a high level of research productivity.

Dr. Hira Mian, MD, MSc, FRCPC

Assistant Professor, Oncology
McMaster University
Hematologist

Juravinski Cancer Centre 
Hamilton, ON 

Dr. Hira Mian, MD, MSc, FRCPC is a hematologist specializing in plasma cell disorders at the Juravinski Cancer Centre in Hamilton, Ontario. She is an assistant professor in the Department of Oncology at McMaster University in Ontario, Canada. Dr. Mian’s research interests include health services and outcomes and care of older adults and frailty in multiple myeloma. Dr. Mian is an active clinical investigator in the Canadian Myeloma Research Group and the Canadian Cancer Trials Group and Board Member of Myeloma Canada.

Dr. Lynne Nakashima, BSc(Pharm), Pharm.D.

Provincial Pharmacy Director
Pharmacy Residency Program Director
BC Cancer Agency
Vancouver, BC

Dr. Lynne Nakashima received her BSc(Pharm) from the University of British Columbia (UBC) and her Pharm.D. from the University of North Carolina at Chapel Hill.  She was awarded a fellowship in the Canadian Association of Pharmacy in Oncology (CAPhO) in 2016.  She is currently the Provincial Pharmacy Director and the Pharmacy Residency Program Director for BC Cancer.  Dr. Nakashima also holds a clinical appointment at the Faculty of Pharmaceutical Sciences at UBC.

Dr. Nakashima is currently responsible for the provincial oncology medication management, supporting the Systemic Therapy drug budgeting, formulary and negotiation processes as well as providing pharmacy leadership across the organization.  She is the lead Pharmacist representing BC Cancer on the Canadian Association of Provincial Cancer Agencies (CAPCA) Drug Supplies Disruptions Team, a national committee that works together to mitigate drug shortages.  With her team at BC Cancer, she coordinates drug shortages within the province, including developing mitigation strategies, coordinating communication and managing inventory.

Professor H. Miles Prince, AM, MBBS (Hons), MD, FRACP, FRCPA, AFRCMA, MACD, FAHMS

Professor, University of Melbourne
Professor, Monash University
Professor/Director of Molecular Oncology and Cancer Immunology, Epworth Healthcare
Director, Centre for Blood Cell Therapies, Peter MacCallum Cancer Centre

Professor Miles Prince is a specialist haematologist who manages all types of blood-related conditions which include anaemia, bleeding and blood clotting disorders, as well as cancers of the blood. He is a full professor at both The University of Melbourne and Monash University.

Professor Prince is involved in major research programs involving stem cell research and the mechanism of the immune systems control of blood and cancer growth. He is also involved in many clinical trials related to this research. He holds major Australian, American and European research grants and has published over 300 journal articles. Professor Prince is a member of Australian, American and European Societies of Haematology and Oncology, and is on the boards of International Society of cutaneous lymphoma, International Waldenstrom’s macroglobulinemia Foundation and chairman of the Medical Scientific Advisory Group of Myeloma Australia. Professor Prince has recently been appointed Director of Molecular Oncology and Cancer Immunology at the Epworth Hospital.

Dr. Noopur Raje, MD

Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Boston, Massachusetts

Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University, India. She has trained in internal medicine at Massachusetts General Hospital (MGH) and has completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute, Boston. Dr. Raje has a joint faculty appointment at MGH and Dana-Farber Cancer Institute. She is a professor of medicine at Harvard Medical School and is the director of the Multiple Myeloma Program, Medical Oncology, at MGH. As a hematologist/oncologist at MGH, Dr. Raje’s primary focus is in multiple myeloma and related research. Her laboratory focuses on bone biology and the development of novel therapeutics for multiple myeloma, as well as identifying and validating novel targets and translating them into clinical trials.

Dr. Raje is a member of the American Medical Association, America Society of Hematology, American Society of Clinical Oncology, and American Association of Cancer Research, she is also an ad hoc reviewer for several journals including Blood, Clinical Cancer Research, Leukemia, and the American Journal of Hematology. Dr. Raje is the recipient of several awards and has published extensively in the field of multiple myeloma research. Her hope is to continue pursing laboratory and clinical research in the area of multiple myeloma with the goal of translating her efforts to the improvement of patients’ lives.